Company
CanBas Co. Ltd
Headquarters: Numazu, Japan
Employees: 12
CEO: Mr. Takumi Kawabe M.D., Ph.D.
Market Cap
¥15.54 Billion
JPY as of Jan. 1, 2025
US$99.0 Million
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $113.24 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $76.33 B |
| Marinomed Biotech AG | $56.13 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
CanBas Co., Ltd., a clinical stage biopharmaceutical company, develops therapeutics for cancer patients. The company develops CBP501, a calmodulin modulator for the treatment of tumors. It also develops CBS9106, a small molecule reversible inhibitor of Exportin-1 that is in Phase I clinical trial for the treatment of solid tumors. The company has a collaboration alliance with Stemline Therapeutics, Inc. CanBas Co., Ltd. was founded in 2000 and is based in Numazu, Japan.
Stocks & Indices
CanBas Co. Ltd has the following listings and related stock indices.
Stock: JPX: 4575 wb_incandescent